Jump to content

Heliyon: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
→Criticism: nothing to do with the journal itself, and that this is a 'problem' needs an actual source
ce
Line 26: Line 26:
'''''Heliyon''''' is a monthly [[peer-reviewed]] [[open-access]] [[mega journal]] covering research in Science, Medicine and Engineering. Its counter-part for Arts, Humanities and Law is journal [[Social Sciences and Humanities Open]]. Unlike most of its competitors, the journal publishes works reporting negative/null results, incremental advances, and replication studies,<ref>https://www.cell.com/heliyon/guide-for-authors</ref> thus filling the market niche, which became vacant after the discontinuation of [[Journal of Negative Results in Biomedicine]] in 2017.
'''''Heliyon''''' is a monthly [[peer-reviewed]] [[open-access]] [[mega journal]] covering research in Science, Medicine and Engineering. Its counter-part for Arts, Humanities and Law is journal [[Social Sciences and Humanities Open]]. Unlike most of its competitors, the journal publishes works reporting negative/null results, incremental advances, and replication studies,<ref>https://www.cell.com/heliyon/guide-for-authors</ref> thus filling the market niche, which became vacant after the discontinuation of [[Journal of Negative Results in Biomedicine]] in 2017.


Helioyn was launched in 2015 by [[Cell Press]], a division of [[Elsevier]]. The journal is divided into numerous sections, each with its own [[editorial board|editorial team]]. All articles are published in Heliyon under a [[CC BY]] [[open access]] license. The [[article processing charge]] in 2024 is 2,160 US$,<ref>https://www.cell.com/heliyon/open-access</ref> although authors from countries eligible for [[Research4Life]]<ref>https://www.research4life.org/access/eligibility/</ref> program may obtain a discount or waiver.<ref>https://www.elsevier.com/researcher/author/open-access/choice</ref>
Heliyon was launched in 2015 by [[Cell Press]], a division of [[Elsevier]]. The journal is divided into numerous sections, each with its own [[editorial board|editorial team]]. All articles are published in Heliyon under a [[CC BY]] [[open access]] license. The [[article processing charge]] in 2024 is 2,160 US$,<ref>https://www.cell.com/heliyon/open-access</ref> although authors from countries eligible for [[Research4Life]]<ref>https://www.research4life.org/access/eligibility/</ref> program may obtain a discount or waiver.<ref>https://www.elsevier.com/researcher/author/open-access/choice</ref>


==Abstracting and indexing==
==Abstracting and indexing==

Revision as of 19:36, 4 September 2024

Heliyon
DisciplineMultidisciplinary
LanguageEnglish
Publication details
History2015–present
Publisher
FrequencyMonthly
Yes
LicenseCC BY
3.4 (2023)
Standard abbreviations
ISO 4Heliyon
Indexing
ISSN2405-8440
OCLC no.934910176
Links

Heliyon is a monthly peer-reviewed open-access mega journal covering research in Science, Medicine and Engineering. Its counter-part for Arts, Humanities and Law is journal Social Sciences and Humanities Open. Unlike most of its competitors, the journal publishes works reporting negative/null results, incremental advances, and replication studies,[1] thus filling the market niche, which became vacant after the discontinuation of Journal of Negative Results in Biomedicine in 2017.

Heliyon was launched in 2015 by Cell Press, a division of Elsevier. The journal is divided into numerous sections, each with its own editorial team. All articles are published in Heliyon under a CC BY open access license. The article processing charge in 2024 is 2,160 US$,[2] although authors from countries eligible for Research4Life[3] program may obtain a discount or waiver.[4]

Abstracting and indexing

The journal is abstracted and indexed in:

References

  1. ^ https://www.cell.com/heliyon/guide-for-authors
  2. ^ https://www.cell.com/heliyon/open-access
  3. ^ https://www.research4life.org/access/eligibility/
  4. ^ https://www.elsevier.com/researcher/author/open-access/choice
  5. ^ "Serials cited". CAB Abstracts. CABI. Retrieved 2021-12-24.
  6. ^ https://scholarlycritic.com/elsevier-unethically-promotes-its-journals-via-scopus-case-of-heliyon.html
  7. ^ "Heliyon". MIAR: Information Matrix for the Analysis of Journals. University of Barcelona. Retrieved 2021-12-24.
  8. ^ https://scholarlycritic.com/elsevier-unethically-promotes-its-journals-via-scopus-case-of-heliyon.html
  9. ^ "Source details: Heliyon". Scopus Preview. Elsevier. Retrieved 2021-12-24.
  10. ^ a b c "Web of Science Master Journal List". Intellectual Property & Science. Clarivate . Retrieved 2021-12-24.
  11. ^ https://mjl.clarivate.com:/search-results?issn=2405-8440&hide_exact_match_fl=true&utm_source=mjl&utm_medium=share-by-link&utm_campaign=search-results-share-these-results
Retrieved from "https://en.wikipedia.org/w/index.php?title=Heliyon&oldid=1244048010"